Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pfizer (PFE) PT Raised to $33 at Goldman Sachs
October 30, 2024 6:16 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Pfizer (NYSE: PFE) to $33.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Despite an impressive headline beat and raise, PFE shares underperformed on the day (-1.4% vs. -0.3% XLV). The 3Q beat was... More
Pfizer (PFE) Tops Q3 EPS by 44c, Beats on Revenue; Offers FY24 Guidance
October 29, 2024 6:46 AM EDTPfizer (NYSE: PFE) reported Q3 EPS of $1.06, $0.44 better than the analyst estimate of $0.62. Revenue for the quarter came in at $17.7 billion versus the consensus estimate of $14.92 billion.
GUIDANCE:
Pfizer sees FY2024 EPS of $2.75-$2.95, versus the consensus of $2.65. Pfizer sees... More
